Engrail Therapeutics

Engrail

This clinical-stage pharmaceutical company develops targeted small-molecule medicines for patients with neuropsychiatric and neurodevelopmental disorders.

Neumora Therapeutics

This biopharmaceutical company develops medicines for patients with neuropsychiatric disorders and neurodegenerative diseases.

Newleos Therapeutics

The company develops oral small-molecule drugs to treat neuropsychiatric disorders, including anxiety and substance use disorders, for patients seeking therapies with fewer side effects.

Draig Therapeutics

The company develops neuromodulators and receptor potentiators for patients with major depressive disorder and other neuropsychiatric conditions.

Autobahn Therapeutics

This company develops brain-penetrating small molecule therapies for patients with neuropsychiatric and neuroimmunologic disorders, including depression and multiple sclerosis.

Kasvu Therapeutics

This company develops small-molecule neuroplastogen treatments for neuropsychiatric and neurodegenerative disorders, targeting patients with major depressive disorder and brain diseases.

Exin Therapeutics

This company develops an artificial intelligence platform to discover and design neurotherapeutics targeting neural circuits for patients with neurological and neuropsychiatric disorders.

Synendos Therapeutics

This company develops small molecule inhibitors to treat patients with central nervous system disorders, such as anxiety and post-traumatic stress disorder.